Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
company
|
| gptkbp:acquisition |
gptkb:Calithera_Biosciences
gptkb:MediGene_AG Plexxikon Incyte_Biosciences_Canada,_Inc. Incyte_Corporation_(Europe)_Ltd. |
| gptkbp:CEO |
Scott_S._Smith
|
| gptkbp:clinicalTrials |
Phase 3 trials
Phase 1 trials Phase 2 trials |
| gptkbp:collaborations |
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim gptkb:Pfizer gptkb:Merck_&_Co. Novartis |
| gptkbp:drugInterdiction |
targeted therapies
vaccines monoclonal antibodies biologics CAR T-cell therapies small molecule inhibitors therapeutic proteins gene therapies RNA-based therapies cell therapies antibody-drug conjugates CRISPR-based therapies biomarker-driven therapies companion diagnostics monoclonal antibody-drug conjugates nucleic acid-based therapies small molecule-drug conjugates |
| gptkbp:employees |
1,500
|
| gptkbp:focusArea |
cancer treatment
|
| gptkbp:founded |
2002
|
| gptkbp:headquarters |
gptkb:Newark,_Delaware
|
| https://www.w3.org/2000/01/rdf-schema#label |
INCY
|
| gptkbp:industry |
biotechnology
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
$12 billion (2021)
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:products |
Jakafi
Iclusig Monjuvi Pemazyre Tazverik |
| gptkbp:researchFocus |
oncology
hematology immunology |
| gptkbp:revenue |
$1.5 billion (2020)
|
| gptkbp:subsidiary |
Incyte_Biosciences_Canada,_Inc.
Incyte_Corporation_(Europe)_Ltd. |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.incyte.com
|